Pfizer Races to Reinvent itself; Profit Collapses Sans Lipitor
- Thread starter Anonymous
- Start date
-
- Tags
- None
So with all the doom and gloom when will the next round to redundancies be coming? I want to go travelling
4th Quarter 2012. Pfizer needs more expense charges to income to mask why it's not meeting core business street expectations and then announce it's buying another mid-size company to "bolt on" for growth.
The sell-offs of nutritional and Animal health, both of which are growing (branded pharmaceutical business is declining year-over-year) is a "spin sell" to put short-term lipstick on the real mid- to long-term systemic problems of Pfizer's old cultures, it's problematic organization, people and lack of innovation and management focus.
The sell-offs of nutritional and Animal health, both of which are growing (branded pharmaceutical business is declining year-over-year) is a "spin sell" to put short-term lipstick on the real mid- to long-term systemic problems of Pfizer's old cultures, it's problematic organization, people and lack of innovation and management focus.
Don't forget the buybacks their doing this year to the tune of~$5B to spoof the P/E numbers specifically to cater to Wall Street and pad their bonuses. What a joke!
as a poster on BioFind so eloquently put it : "...selling the niche businesses that MAKE money in order to return to the core business of LOSING money" as the sites they clumsily tried to close but couldn't (Pearl River, Sandwich) suck cash like giant leeches from a mother ship that slowly sinks into the swamp 
oh who cares next year after the animal health chips have been cashed in Ian will finally have enough leverage to gobble up their #2 choice after Wyeth (= Amgen) because they can't afford to lose Enbrel in 2013, especially given the new IP that essentially makes Enbrel immune to generic competition for the forseeable future.
we all remember the last time a very lucrative drug (lipitor) was about to slip between their fingers when the bride (Warner-Lambert) marched to the altar with the wrong groom (AHP) ...
http://www.nasdaq.com/article/amgen...-sales-duties-for-enbrel-in-us-20120418-01723 in 2013...
http://pacbiztimes.com/2011/12/23/patent-ruling-a-lucrative-gift-for-amgen/
oh who cares next year after the animal health chips have been cashed in Ian will finally have enough leverage to gobble up their #2 choice after Wyeth (= Amgen) because they can't afford to lose Enbrel in 2013, especially given the new IP that essentially makes Enbrel immune to generic competition for the forseeable future.
we all remember the last time a very lucrative drug (lipitor) was about to slip between their fingers when the bride (Warner-Lambert) marched to the altar with the wrong groom (AHP) ...
http://www.nasdaq.com/article/amgen...-sales-duties-for-enbrel-in-us-20120418-01723 in 2013...
http://pacbiztimes.com/2011/12/23/patent-ruling-a-lucrative-gift-for-amgen/